aTyr Pharma, Inc.(ATYR) - 2024 Q3 - Quarterly Results

Financial Performance - Total revenues for Q3 2024 were $0, compared to$353,000 in Q3 2023, indicating a decrease in license and collaboration agreement revenues[12] - Consolidated net loss for Q3 2024 was $17.3 million, compared to a net loss of$11.3 million in Q3 2023[12] - General and administrative expenses for Q3 2024 were $3.3 million, compared to$2.6 million in Q3 2023[12] - Research and development expenses for Q3 2024 were $14.8 million, up from$10.3 million in Q3 2023, reflecting increased clinical trial costs[7] Cash and Investments - Cash and investments as of September 30, 2024, were $68.9 million, down from$101.7 million at the end of 2023[13] - Total assets as of September 30, 2024, were $91.6 million, down from$120.7 million at the end of 2023[13] - The company raised approximately $19.4 million in gross proceeds from an at-the-market offering after Q3 2024[7] Clinical Trials - Enrollment completed in the Phase 3 EFZO-FIT™ study with 268 patients, exceeding the target, and topline data expected in Q3 2025[5] - The Phase 2 EFZO-CONNECT™ study is ongoing, aiming to enroll up to 25 patients with interim data expected in Q2 2025[6] - The efzofitimod program showed statistically significant improvement in corticosteroid relapse rates, as published in the European Respiratory Journal[2]